JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Determine the Absorption, Metabolism, and Routes of Excretion of (14C) Radiolabeled Ibrutinib in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Ibrutinib

First Posted Date: 2012-08-28

Last Posted Date: 2014-11-05

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 6

Registration Number: NCT01674322

An Expanded Access Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Who Have Completed Clinical Study COU-AA-001

Phase 1

Completed

Conditions: Prostate Neoplasms

Interventions: Drug: Abiraterone acetate
Drug: Glucocorticoid

First Posted Date: 2012-08-14

Last Posted Date: 2013-04-19

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 54

Registration Number: NCT01664728

An Efficacy Study of Paliperidone for the Prevention of Relapse in Participants With Schizophrenia

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: Placebo
Drug: Paliperidone

First Posted Date: 2012-08-10

Last Posted Date: 2014-09-29

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 201

Registration Number: NCT01662310

A Study to Assess the Effects of 2 Different Prothrombin Complex Concentrates on the Pharmacodynamics of Rivaroxaban in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Rivaroxaban 20 mg twice daily
Drug: Rivaroxaban 20 mg once daily
Other: Saline
Drug: Profilnine SD
Drug: Beriplex P/N

First Posted Date: 2012-08-03

Last Posted Date: 2017-01-24

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 35

Registration Number: NCT01656330

A Study to Evaluate Safety, Acceptability, Pharmacokinetics, and ex Vivo Pharmacodynamics of TMC278 Long Acting Formulation in HIV-1 Seronegative Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: TMC278, Long acting (LA)

First Posted Date: 2012-08-02

Last Posted Date: 2016-04-07

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 4

Registration Number: NCT01656018

A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Abiraterone in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Abiraterone acetate
Drug: Rifampicin

First Posted Date: 2012-08-01

Last Posted Date: 2013-01-10

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 19

Registration Number: NCT01655147

Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy

Phase 3

Completed

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Temsirolimus
Drug: Ibrutinib

First Posted Date: 2012-07-20

Last Posted Date: 2018-01-19

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 280

Registration Number: NCT01646021

A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy

Phase 2

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Ustekinumab + MTX (Group 2)
Drug: Ustekinumab + MTX (Group 3)
Drug: Placebo + methotrexate (MTX) (Group 1)
Drug: CNTO 1959 + MTX (Group 4)
Drug: CNTO 1959 + MTX (Group 5)

First Posted Date: 2012-07-20

Last Posted Date: 2016-05-12

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 274

Registration Number: NCT01645280

A Study to Evaluate the Effects of Domperidone on Cardiac Repolarization in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Treatment A (domperidone 10 mg)
Drug: Treatment B (domperidone 20 mg)
Drug: Treatment C (placebo)
Drug: Treatment D (moxifloxacin)

First Posted Date: 2012-07-18

Last Posted Date: 2013-06-24

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 44

Registration Number: NCT01643889

A Comparative Study of Bioavailability of 3 New Abiraterone Acetate Tablets With Current Commercial Tablet

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Abiraterone acetate, 250 mg (coated, reformulated tablet)
Drug: Abiraterone acetate, 500 mg (coated tablet, slower in vitro dissolution)
Drug: Abiraterone acetate, 250 mg (uncoated, current commercial tablet)
Drug: Abiraterone acetate, 500 mg (coated, reformulated tablet)

First Posted Date: 2012-07-13

Last Posted Date: 2013-03-04

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 32

Registration Number: NCT01640093

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy